ReviewCell death & disease2026
Decoding the CAF-TAM axis: multi-omics dissection and therapeutic targeting of stromal-immune crosstalk in the tumor microenvironment.
Review in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Research advances on tumor-associated macrophages in pancreatic cancer.Biochemistry and biophysics reports · 2026Review
- Cancer drug response and resistance: molecular mechanisms and combating strategies.Signal transduction and targeted therapy · 2026Review
- The Evolving Landscape of Immune Regulation and Immunotherapy in Cholangiocarcinoma and Biliary Tract Cancer.Cancers · 2026Review
- Mechanisms and therapeutic strategies of bidirectional crosstalk between hepatic stellate cell-derived cancer-associated fibroblasts and T cells in immune evasion and therapeutic resistance of hepatocellular carcinoma.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs) are pivotal stromal and immune components of the tumor microenvironment (TME) that orchestrate immune evasion, metabolic reprogramming, and therapeutic resistance. Regions enriched in CAFs are frequently accompanied by dense TAM infiltration, underscoring their close structural and functional interdependence. Recent advances in single-cell, multi-omics, and spatial profiling technologies have revolutionized our understanding of the spatiotemporal heterogeneity, lineage evolution, and bidirectional signaling between CAFs and TAMs. In this review, we summarize the latest progress from transcriptomic, epigenomic, metabolomic, and spatial multi-omics studies, highlighting the diverse CAF/TAM subpopulations, their intercellular communication networks, and their collective roles in extracellular matrix remodeling, immune suppression, metabolic adaptation, and angiogenesis. Finally, we discuss emerging therapeutic strategies targeting CAFs, TAMs, and their interactive pathways, offering new conceptual and translational insights into reprogramming the immunosuppressive TME and enhancing antitumor efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.